- Home
- ASMB vs LFCR Comparison
ASMB vs LFCR Comparison
Compare ASMB & LFCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- LFCR
- Stock Information
- Founded
- ASMB 2005
- LFCR 1986
- Country
- ASMB United States
- LFCR United States
- Employees
- ASMB N/A
- LFCR N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- LFCR Biotechnology: Pharmaceutical Preparations
- Sector
- ASMB Health Care
- LFCR Health Care
- Exchange
- ASMB Nasdaq
- LFCR Nasdaq
- Market Cap
- ASMB 225.9M
- LFCR 256.6M
- IPO Year
- ASMB 2010
- LFCR N/A
- Fundamental
- Price
- ASMB $37.28
- LFCR $7.84
- Analyst Decision
- ASMB Strong Buy
- LFCR Hold
- Analyst Count
- ASMB 6
- LFCR 3
- Target Price
- ASMB $43.40
- LFCR $6.00
- AVG Volume (30 Days)
- ASMB 133.7K
- LFCR 164.0K
- Earning Date
- ASMB 11-10-2025
- LFCR 01-02-2026
- Dividend Yield
- ASMB N/A
- LFCR N/A
- EPS Growth
- ASMB N/A
- LFCR N/A
- EPS
- ASMB N/A
- LFCR N/A
- Revenue
- ASMB $37,191,000.00
- LFCR $128,867,000.00
- Revenue This Year
- ASMB $14.29
- LFCR $4.72
- Revenue Next Year
- ASMB N/A
- LFCR $10.97
- P/E Ratio
- ASMB N/A
- LFCR N/A
- Revenue Growth
- ASMB 31.30
- LFCR 0.47
- 52 Week Low
- ASMB $7.75
- LFCR $4.76
- 52 Week High
- ASMB $39.71
- LFCR $8.85
- Technical
- Relative Strength Index (RSI)
- ASMB 66.12
- LFCR 58.37
- Support Level
- ASMB $35.50
- LFCR $7.28
- Resistance Level
- ASMB $39.65
- LFCR $7.96
- Average True Range (ATR)
- ASMB 2.14
- LFCR 0.43
- MACD
- ASMB 0.05
- LFCR 0.02
- Stochastic Oscillator
- ASMB 72.27
- LFCR 64.74
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.